Boston Scientific has acquired Rhythmia Medical, a privately held company based in Burlington, Massachusetts.
The transaction for Rhythmia Medical, the developer of next-generation mapping and navigation solutions for use in the cardiac catheter ablation and other electrophysiology procedures, including atrial fibrillation and atrial flutter, is likely to be completed by Friday 12th October.
Electrophysiology is certainly an attractive market for Boston Scientific, with a volume of $2.5 billion and double-digit growth, which would be a significant growth opportunity for the company.
Atrial fibrillation is a disorder that interferes with the ability of the heart to beat regularly considerably. About 15 million people are affected worldwide. The catheter, through a three-dimensional mapping and navigation process, is commonly used to treat many cardiac arrhythmias, including atrial flutter and atrial fibrillation.
[ilink url=“http://salesandmarketingnetwork.com/news_release.php?ID=2035792″] Link zur Quelle (Sale and Marketingnetwork)[/ilink]